Miplyffa Uptake Makes Zevra a Tradeable Rare-Disease Win — Buy on Strength, Ride the Commercial Setup
Zevra Therapeutics' initial commercial uptake of MIPLYFFA and a $150M Rare Pediatric Disease Voucher sale materially de-risk the company’s move from clinical-stage to commercial-stage rare disease franchising. With a market cap near $620M and an improving top-line setup, we recommend a tactical long position for investors willing to tolerate biotec…